



The Prognostic Role of Decaf and Bap 65 Scores in Predicting Outcomes Among Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Presenting to The Emergency Department of A Tertiary Care Centre In Chennai

¹Dr.Revathi Rajendran, Post Graduate Student, Department of General Medicine, Government Stanley Medical College, Chennai

²Prof. Dr. I. Rohini, M.D., (Guide), Unit Chief, Department of General Medicine, Stanley Medical College & Hospital, Chennai

³Prof. Dr. S. Parimalasundari, M.D., HOD, Department of General Medicine, Stanley Medical College & Hospital, Chennai

Corresponding Author: Dr. Revathi Rajendran, Post Graduate Student, Department of General Medicine, Government Stanley Medical College, Chennai

How to citation this article: Dr. Revathi Rajendran, Prof. Dr. I. Rohini, Prof. Dr. S. Parimalasundari, “The Prognostic Role of Decaf and Bap 65 Scores in Predicting Outcomes Among Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Presenting to The Emergency Department of A Tertiary Care Centre In Chennai”, IJMACR- January - 2025, Volume – 8, Issue - 1, P. No. 236 – 245.

Open Access Article: © 2025 Dr. Revathi Rajendran, et al. This is an open access journal and article distributed under the terms of the creative common’s attribution license (<http://creativecommons.org/licenses/by/4.0>). Which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease that is characterized by persistent airflow limitation which is usually progressive and associated with enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases. COPD is the fourth most frequent cause of death after ischemic heart disease, cerebrovascular disease and malignancy. COPD is a common cause of mortality and morbidity worldwide. Acute exacerbation of COPD is an acute event characterized by worsening of patient’s symptoms that is

beyond normal day to day variation and leads to a change in medication. Exacerbations accelerate the rate of decline of lung function and are associated with significantly higher mortality.

Aim: To compare DECAF and BAP-65 SCORE in predicting the outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease.

Objective: To apply DECAF and BAP65 scoring systems on patients who present with acute exacerbation of COPD and to study the outcomes and to predict the better prognostic scoring system.

Expected Outcome and Benefit of Study: To identify high risk patient earlier with the better scoring system so as to assess the need for early intervention and easier risk stratification.

Methodology

Study Design: Hospital based prospective observational study.

Study Centre: ED, Government Stanley Medical College and Hospital.

Study Period: July 2021 to September 2022.

Study Population: Patients presenting to the emergency department with acute exacerbation of chronic obstructive pulmonary disease.

Result: A total of 130 patients were included in the study. The mortality rate was 58.8% (n=130). Mortality rates patients hospitalised with acute exacerbation of Chronic Obstructive Pulmonary Disease with DECAF scores > 3. The sensitivity of DECAF and BAP65 scores for prediction of mechanical ventilation need was 86.21% and 72.41%, respectively, whereas the specificity of was 68.32% and 31.68%, respectively, with 72.31% accuracy in DECAF score and 40.77% accuracy in BAP65 class. A positive significant correlation was found between DECAF score and BAP65 class (r=0.293, p=0.001).

Conclusion: In conclusion, a clinical prediction tool must be applicable, reliable, and beneficial. Both scores are practical in the sense that they can be easily calculated by asking simple questions and conducting routine laboratory tests. The BAP65 scoring system includes variable that are non invasive and quick to apply on a patient that is presenting to the ED, but it is also seen that its ease of use has not proven it to be a better scoring system in our analysis. In spite of the

small sample size, DECAF score excels in predicting the mortality and the need for mechanical ventilation.

Keywords: Acidemia, Cerebrovascular Disease, Dyspnoea, Higher Mortality, Ischemic Heart Disease.

Introduction

Chronic obstructive pulmonary disease (COPD) is a disease that can be prevented and treated that is characterised by persistent airflow limitation that is typically progressive and associated with enhanced chronic inflammatory response in the airways and lungs to noxious particles or gases. COPD can be prevented by maintaining a healthy weight, quitting smoking, and getting regular exercise. Worldwide, chronic obstructive pulmonary disease (COPD) is a common cause of death and illness, as of now it is the number 4th cause of death worldwide.

Diagnosis of acute exacerbation of chronic obstructive pulmonary disease is mainly based on clinical presentation of increasing dyspnoea, increasing quantity and change in quality of sputum. A panel of bio markers are yet to be identified for diagnosing an exacerbation. Multiple prognostic indices related to poorer outcomes and higher death rates in AECOPD have been developed. Two such scoring systems are the DECAF and BAP65 scores. The DECAF score includes dyspnoea, eosinopenia $<0.05 \times 10^9 /L$, consolidation on chest X-ray, acidemia pH <7.30 , atrial fibrillation. BAP-65 score includes BUN >25 mg/dL, altered mental status (initial GCS <14 , or disorientation, stupor, or coma), pulse >109 beats /min, age 41-64 or 65. Both scores predict morbidity and mortality in AECOPD and help in risk stratification of patients and thereby assessing the need for earlier intervention.

Aim and Objectives

Aim: To compare DECAF and BAP-65 SCORE in predicting the outcomes and prognosis in patients admitted with acute exacerbation of chronic obstructive pulmonary disease to the ED .

Objective: To apply DECAF and BAP65 scoring systems on patients who present with acute exacerbation of COPD and to study the outcomes and to predict the better prognostic scoring system, thereby helping in better risk stratification of patient.

Material and Methods

Study Design: Hospital based prospective observational study.

Study Centre: ED, Government STANLEY Medical College and Hospital

Study Period: JULY 2021 TO SEPTEMBER 2022

Study Population: Patients presenting to the emergency department with acute exacerbation of chronic obstructive pulmonary disease.

Inclusion Criteria

1. Patients with a primary diagnosis of acute exacerbation of COPD
2. Adults >40 years
3. Patients giving informed consent.

Exclusion Criteria

1. Patients in whom primary reason for admission were cause were expressed as Mean and Standard Deviation. All other than acute exacerbation of COPD were excluded from the study. Hence patients with the following disease were excluded from the study
 - Bronchial asthma - acute exacerbation
 - Bronchiectasis - acute exacerbation
 - Interstitial lung disease - exacerbation
 - Lung cancer
 - Traumatic pneumothorax.
 - Congestive cardiac failure

- Acute on chronic decompensated liver or renal disease
2. Patient who do not wish to participate.
 3. Pregnant patient.

Sample size: N = 130

Formula

$$n = Z^2pq / d^2$$

Where Z = 1.96 (statistical significant constant for 95% CI)

p = 58.8 % (Mortality rates patients hospitalised with acute exacerbation of Chronic Obstructive Pulmonary Disease with DECAF scores > 3 (4 & 5) from previous study.)

$$q = 41.2 \% (100-p)$$

$$d = 15\% \text{ relative precision (ie } 15\% \text{ of } 58.8=8.9)$$

On substituting, in the formula $n = 3.84 \times 58.8 \times 41.2 / 79.2$

$$n = 117$$

Adding 10% non-response rate (ie 10% of 117 = 12) n = 129 (minimum sample size)

Therefore, Sample size n = 130 (1 group).

Statistical analysis

After collection, the data were compiled and entered in Microsoft Excel sheet. Analysis were done using Statistical software version 16. All continuous variables were expressed as Mean and Standard Deviation. All categorical variables were expressed as percentages and proportions. Chi-Square test is used as test of significance. P value of <0.05 Confidence Interval (CI).


Results

Table 1: Distribution of age among the study participants (N=130)

Sn	Age	Frequency	Percentage
1	41-50	28	21.5
2	51-60	40	30.8

3	61-70	37	28.5
4	71-80	20	15.4
5	>80	5	4.8

Figure 1: Distribution of age among the study participants (N=130)




Around 21.5% 41-50 years, 30.8% 51-60 years, 28.5% 61-70 years, 15.4% 71-80 years and 4.8% >80 years.

Table 2: Distribution of gender among the study participants (N=130)

Sn	Gender	Frequency	Percentage
1	Female	14	10.8
2	Male	116	89.2

Figure 2: Distribution of gender among the study participants (N=130)




Around 10.8% were females and 89.2% males.

Table 3: Distribution of comorbidities among the study participants (N=130)

Sn	Comorbidities	Frequency	Percentage
1	Systemic hypertension	6	4.6
2	Diabetes mellitus and Systemic hypertension	1	0.7
3	PTB sequelae	22	16.9
4	Chronic kidney disease	2	1.5
5	Others	12	9.2

Figure 3: Distribution of comorbidities among the study participants (N=130)




Around 4.6% were having systemic hypertension, 0.7% Diabetes mellitus and Systemic hypertension, 16.9% PTB sequelae, 1.5% Chronic kidney disease and 9.2% others.

Table 4: Distribution of corpulmonale among the study participants (N=130)

Sn	Corpulmonale	Frequency	Percentage
1	Mild pulmonary hypertension	13	10.0
2	Moderate pulmonary hypertension	4	3.1
3	Sever pulmonary hypertension	21	16.2
4	No	92	70.8

Figure 4: Distribution of corpulmonale among the study participants (N=130)




About 10% with Mild pulmonary hypertension, 3.1% Moderate pulmonary hypertension and 16.2% Sever pulmonary hypertension.

Table 5: Distribution of dyspnea among the study participants (N=130)

Sn	Dyspnea	Frequency	Percentage
1	4	33	25.4
2	5a	27	20.8
3	5b	70	53.8

Figure 5: Distribution of dyspnea among the study participants (N=130)



Around 25.4% with grade 4 dyspnea, 20.8% with grade 5a and 53.8% with grade 5b.

Table 6: Distribution of DECAF score among the study participants (N=130)

Sn.	DECAF score	Frequency	Percentage
1	0	31	23.8

2	1	13	10
3	2	15	11.5
4	3	14	10.8
5	4	51	39.2
6	5	6	4.6

Figure 6: Distribution of DECAF score among the study participants (N=130)




Table 7: Distribution of altered mental status among the study participants (N=130)

Sn.	Altered mental status	Frequency	Percentage
1	Yes	52	40
2	No	78	60

Figure 7: Distribution of altered mental status among the study participants (N=130)




Table 8: Distribution of pulse rate among the study participants (N=130)

Sn.	Pulse rate	Frequency	Percentage
1	≥ 109 beats/min	65	50

2	<109 beats/min	65	50
---	----------------	----	----

Figure 8: Distribution of pulse rate among the study participants (N=130)





Table 9: Distribution of BAP65 class among the study participants (N=130)

Sn.	BAP65	Frequency	Percentage
1	Class 1	27	20.8
2	Class 2	13	10
3	Class 3	37	28.5
4	Class 4	25	19.2
5	Class 5	28	21.5

Figure 9: Distribution of BAP65 score among the study participants (N=130)




Around 20.8% in class 1, 10% in class 2, 28.5% Class 3, 19.2% Class 4 and 21.5% in Class 5.

Table 10: Distribution of use of ventilation among the study participants (N=130)

Sn.	Ventilation	Frequency	Percentage
1	Yes	29	22.3

2	No	101	77.7
---	----	-----	------

Figure 10: Distribution of use of ventilation among the study participants (N=130)



Around 22.3% had ventilation.

Table 11: Distribution of BAP65 class in predicting the outcome among the study participants (N=130)

Sn.	BAP65 class	Outcome	
		Mortality	No mortality
1	≥ 3	13	77
2	<3	7	33

Statistic	Value	95% CI
Sensitivity	65.00%	40.78% to 84.61%
Specificity	30.00%	21.63% to 39.48%
Positive Likelihood Ratio	0.93	0.66 to 1.31
Negative Likelihood Ratio	1.17	0.60 to 2.26
Disease prevalence	15.38%	9.66% to 22.76%
Positive Predictive Value	14.44%	10.69% to 19.24%
Negative Predictive Value	82.50%	70.86% to 90.14%
Accuracy	35.38%	27.20% to 44.25%

Figure 11: Distribution of BAP65 class in predicting the outcome among the study participants (N=130)




Table 12: Association of outcome between DECAF and BAP65 score among the study participants (N=130)

Sn.	Variable	Mortality	Status quo	Improved	X ² (df), p
1	DECAF Score	20 (100)	6 (54.4)	31 (31.3)	32.44 (1) <0.001
	≥ 3	0 (0)	5 (45.5)	68 (68.7)	
	<3				
2	BAP65 Class	13 (65)	9 (81.8)	68 (68.7)	1.00 (1) 0.61
	≥ 3	7 (35)	2 (18.2)	31 (31.3)	
	<3				

It was seen that patients with a higher DECAF score predicted mortality of the patients at the time of admission better than the DECAF score. It is seen that the BAP class of less than 3 had also shown mortality.

Table 13: Association of ventilation between DECAF and BAP65 score among the study participants (N=130)

Sn.	Variable	Ventilation		p
		Yes	No	
1	DECAF Score			27.21 (1), <0.001
	≥ 3	25 (86.2)	32 (31.7)	
	<3	4 (13.8)	69 (68.3)	
2	BAP65 Class			0.65 (1), 0.72
	≥ 3	21 (72.4)	69 (68.3)	
	<3	8 (27.6)	32 (31.7)	

The need of use of ventilation was predicated by the DECAF scoring system better than by the BAP65 scoring system.

Discussion

Research on the prognosis of hospitalization-required exacerbations of chronic obstructive pulmonary disease (COPD) has been limited, and there appears to be little overlap between predictors of mortality in stable disease and AECOPD. In addition, none of the prognostic tools developed for stable disease have been evaluated on hospitalised patients, and the majority of them require clinical measurements that are not routinely available at hospital admission.

Our study is aimed to compare DECAF and BAP-65 SCORE in predicting the outcomes and prognosis in patients admitted with acute exacerbation of chronic obstructive pulmonary disease to the Emergency department of a tertiary care centre in Chennai.

In our study for AUROC for predication for DECAF score was 0.83. A Study conducted Sashideep Reddy et al revealed that DECAF had higher sensitivity and higher chance of prediction of mortality than the BAP 65 score.

The sensitivity of DECAF and BAP65 scores for prediction of mechanical ventilation need was 86.21% and 72.41%, respectively, whereas the specificity of was 68.32% and 31.68%, respectively, with 72.31% accuracy in DECAF score and 40.77% accuracy in BAP65 class. A positive significant correlation was found between DECAF score and BAP65 class (r=0.293, p=0.001).

Conclusion

Though both the scoring systems have been proven to have good predictive values when individually analyzed, in our study we conclude that DECAF score has good prediction of mortality, hospital stay and the need for mechanical ventilation than BAP65 class scoring system.

In conclusion, a clinical prediction tool must be applicable, reliable, and beneficial. Both scores are practical in the sense that they can be easily calculated by asking simple questions and conducting routine laboratory tests. The BAP65 scoring system includes variables that are noninvasive and quick to apply on a patient that is presenting to the ED, but it is also seen that its ease of use has not proven it to be a better scoring system in our analysis. In spite of the small sample size, DECAF score excels in predicting the mortality and the need for mechanical ventilation. Therefore, DECAF score may be used routinely in clinical judgement and patient triage, i.e., to determine which patients should receive ventilator support.

References

1. O'Donnell DE, Parker CM. COPD exacerbations: pathophysiology. *Thorax* 2006;61:354–361.
2. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. *Ann Intern Med* 2001;134:600–620.
3. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. *Chest* 1995;108:43S–52S.
4. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 2007;29:1224–1238.
5. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. *Chest* 2000;117:5S–9S.
6. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. *Respir Care* 2002;47:1184–1199.
7. Ramsey SD, Berry K, Etzioni R, Kaplan RM, Sullivan SD, Wood DE; National Emphysema Treatment Trial Group. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. *N Engl J Med* 2003;348:2092–2102.
8. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med* 2006;173:1114–1121.
9. Fagon JY, Chastre J, Trouillet JL, Domart Y, Dombret MC, Bornet M, Gilbert C. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis use of the protected specimen brush technique in 54 mechanically ventilated patients. *Am Rev Respir Dis* 1990;142:1004–1008.
10. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;152:1316–1320.
11. J Steer, EM Norman, OA Afolali, GT Gibson, SC Bourke. Dysnea severity and Pneumonia as predictors of In-hospital mortality and early readmission in acute exacerbation of COPD. *Thorax*. 2012;67(2):117-121.
12. Gil H, Magy N, Mauny F, Dupond JL (2003) Value of eosinopenia in inflammatory disorders: an “old” marker revisited. *Rev Med Interne* 24: 431–435.
13. Abidi K, Belayachi J, Derras Y, Khayari ME, Dendane T, et al. (2011) Eosinopenia, an early marker of increased mortality in critically ill medical patients. *Intensive Care Med* 37: 1136–1142.

14. Shaaban H, Daniel S, Sison R, Slim J, Perez G (2010) Eosinopenia: Is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? *J Crit Care* 25: 570– 575
15. Holland M, Alkhalil M, Chandromouli S, Janjua A, Babores M (2010) Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. *Respirology* 15: 165– 167.
16. Royal College of Physicians, British Thoracic Society, British Lung Foundation. Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: Clinical Audit of COPD Exacerbations Admitted to Acute NHS Trusts across the UK. London: Royal College of Physicians, 2008.
17. Davidson C. 2010 Adult Non-Invasive Ventilation Audit Summary Report. The British Thoracic Society, 2011.
18. Tabak YP, Sun X, Johannes RS, et al. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score. *Arch Intern Med* 2009; 169:1595-602.
19. Hagaman JT, Rouan GW, Shipley RT, et al. Admission chest radiograph lacks sensitivity in the diagnosis of community-acquired pneumonia. *Am J Med Sci* 2009;337:236-40.
20. Roche N, Zureik M, Soussan D, et al. Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. *Eur Respir J* 2008;32:953e61.
21. Thomas AJ, Valabhji P. Arrhythmia and tachycardia in pulmonary heart disease. *Br Heart J* 1969; 31: 491–495.
22. Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. *Chest* 2002;122:1264e70.
23. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. *Am Heart J* 1983; 105: 311–315.
24. Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD – clinical practice guideline, part 1. *Chest* 2001; 119: 1185–1189.
25. Yan Cheng, Matthew E Borrego, Floyd J Frost, Hans Petersen and Dennis W Raisch. . Predictors for mortality in hospitalized patients with chronic obstructive pulmonary disease. SpringerPlus 2014, 3:359.
26. Steer, J., Gibson, J., & Bourke, S. C. (2012). The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax*, 67(11), 970-976.
27. Sangwan, V., Chaudhry, D., & Malik, R. (2017). Dyspnea, eosinopenia, consolidation, acidemia and atrial fibrillation score and BAP-65 score, tools for prediction of mortality in acute exacerbations of chronic obstructive pulmonary disease: a comparative pilot study. *Indian Journal of Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine*, 21(10), 671.
28. Zidan, M. H., Gharraf, H. S., & Wahdan, B. E. (2020). A comparative study of DECAF score and modified DECAF score in predicting hospital mortality rates in acute exacerbation of chronic obstructive pulmonary disease. *The Egyptian Journal of Chest Diseases and Tuberculosis*, 69(3), 532.

29. Manchu, D., & Sv, S. (2020). Prediction of Outcomes in Acute Exacerbation of COPD with Decaf Score and BAP 65 Scores in a Rural Population. *The Journal of the Association of Physicians of India*, 68(1), 80.
30. TelukuTla, S. R., Vidya, T., & GANESAN, N. (2020). BAP 65 and DECAF scores in Predicting Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Prospective Observational Study. *Journal of Clinical & Diagnostic Research*, 14(11).